Good News: National Pharmaceutical Pricing Authority reduces price of stents

Medisense Team
Editorial Team
Feb 15

The National Pharmaceutical Pricing Authority (NPPA) Monday further slashed prices of the expensive cardiac stents while marginally increasing the cost of the basic stents.

After several rounds of consultation with various stakeholders, the NPPA cut the price of drug-eluting stent (DES) by Rs 1,710 (from Rs 29,600 to Rs 27,890) while increasing the price of bare metal stent (BMS) by Rs 400 (from Rs 7,260 to Rs 7,660).

The trade margin has been capped at 8%, the NPPA said in an order, which makes the current rates valid till March 31.

“All manufacturers of coron...

35- Views


Medisense Healthcare collaborate with Parkway Hospitals, Singapore to offer 'top-of-the-line' healthcare services and facilities

Medisense Team
Editorial Team
Feb 14

Medisense Healthcare Solutions recently signed an agreement with Parkway hospitals, Singapore for a medical collaboration to provide a one-stop service for Indian & International patients looking for specialists' expertise, personalised patient care and cutting-edge technology at Mount Elizabeth Hospitals, Singapore.

With medical costs about half of those of US, Singapore has been positioning itself as a destination for modern medical technology with highly trained doctors. It ranks 6th among 191 countries with advanced health systems in the...

327- Views


MNCs demand stent price revision

Medisense Team
Editorial Team
Feb 12

While multi-national companies are pushing for an increase in the price of cardiac stents, domestic manufacturers are more than happy with the price ceilings introduced by the Centre last year.

In less than two weeks, the National Pharmaceutical Pricing Authority (NPPA) will decide whether the prices of cardiac stents should be revised or not. In lieu of the impending decision, the pricing regulator held a stakeholders' consultation earlier this week with multinational companies, domestic manufacturers, importers and distributors as well as civil society representatives, to take in ...

63- Views


Novel blood test may help you measure your heart health

Medisense Team
Editorial Team
Feb 10

London: Researchers have found a new blood test that could provide a clue as to why some patients are at a higher risk of cardiovascular disease risk after suffering a heart attack.

The results showed novel therapies targeting fibrin clot lysis time may improve prognosis in patients with acute coronary syndrome.

"Our findings provide exciting clues as to why some patients are at higher risk after a heart attack and how we might address this with new treatments in the future," said co-author of the study Rob Storey, a professor from the University of Sheffield, UK.


42- Views


Treatment against blindness to sell for $850,000 in US

Medisense Team
Editorial Team
Feb 09

There are currently about 1,000 cases of people who suffer from hereditary degeneration of the retina, and 10 to 20 new cases are expected to be added each year.

Luxturna, a medication against hereditary degeneration of the retina that can lead to total blindness, will be sold for $850,000 in the United States, making it one of the world’s most expensive medical treatments.

It is administered in a single dose, according to its manufacturer, Philadelphia-based Spark Therapeutics.

It will retail for $425,000 per eye, which is less than the $1 million price tag th...

29- Views


We are an online platform for patients to receive online medical opinion, treatment options & patient assistance by disease specific expert panelists.

We help patients in understanding

  • Correctness of diagnosis & current treatment
  • Available Treatment options in India and abroad by Allopathy, Ayurveda & other sciences of Medicine.
  • Right doctor and hospital for the treatment, and cost associated with it.
  • Medical Visa, Travel & accommodation support for domestic and international patients.
  • Unbiased medical opinion at the comfort of home
  • Treatment options & patient assistance like Medical Visa, travel, accommodation all under one roof.
  • Disease specific panel to guide patients from both allopathic & Ayurveda.
  • Trusted brand worldwide, with a mission "Medical Miracles".

Patients to submit their medical query along with the reports and Medisense panel gives an unbiased opinion within 24 to 48 Hrs. Click here to submit the query.

Super Specialties